Simoni, D., Grisolia, G., Giannini, G., Roberti, M., Rondanin, R., Piccagli, L., Baruchello, R., Rossi, M., Romagnoli, R., Invidiata, F.P., Grimaudo, S., Jung, M.K., Hamel, E., Gebbia, N., Crosta, L., Abbadessa, V., Di Cristina, A., Dusonchet, L., Meli, M. and Tolomeo, M. (2005) Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apopto-Sis-Inducing Activity in HL60 And in MDR Cell Lines. Journal of Medicinal Chemistry, 48, 723-736.
https://doi.org/10.1021/jm049622b

has been cited by the following article:

• TITLE: Molecular Modeling and Synthesis of New Heterocyclic Compounds Containing Pyrazole as Anticancer Drugs

  AUTHORS: Fiby N. Takla, Abdelbasset A. Farahat, Magda A.-A. El-Sayed, Magda N. A. Nasr

  KEYWORDS: Tubulin, CA-4, Anticancer, Pyrazole, Molecular Modeling

  JOURNAL NAME: International Journal of Organic Chemistry, Vol.7 No.4, December 15, 2017

  ABSTRACT: Several modifications in CA-4 were reported in literature for the development of various tubulin inhibitors. In our study, twenty-two newly synthesized heterocyclic derivatives of Combretastatin A-4 (CA-4) have been tested for their cytotoxic effect on four different types of cells with malignant behavior using CA-4 as a positive control. Compounds 5b, 15 and 16 showed the foremost potent antiproliferative activities as compared to CA-4 with IC50 starting from 6.9 to 13.7 μM. Molecular docking was performed with the crystal structure of tubulin employing a potent tubulin inhibitor CA-4 as a parent molecule. Molecular study advised that 5b, 15, 16 and 17 are promising tubulin inhibitors.